Jubilant Pharmova Delivers 21% Revenue Growth in Q2 FY27 with Rs. 800 Crore Debt Refinancing
Earnings rise to Rs. 2,370 crore while EBITDA margins decline amid remediation costs and product availability issues
Jubilant Pharmova Limited announced a 21% year-on-year revenue increase to Rs. 2,370 crore for Q2 FY27, driven by growth in all business segments including Radiopharmaceuticals, Radiopharmacy, Allergy Immunotherapy, and CDMO Sterile Injectables. Despite a decline in EBITDA margin to 10.7%, the company emphasized robust segmental expansion and successful capital raising of Rs. 800 crore through Non-convertible debentures to refinance debt and support capex plans.
Jubilant Pharmova Limited
General / Other
Jubilant Pharmova Limited posted a 21% year-on-year revenue increase to Rs. 2,370 crore in Q2 FY27, driven by broad-based business expansion and strategic agreements, alongside raising Rs. 800 crore via Non-convertible debentures to refinance debt and fund investments.
Revenue growth was strong across all business segments, notably a 33% rise in CDMO Sterile Injectables revenue to Rs. 522 crore driven by technology transfers and new manufacturing lines.
EBITDA for Q2 FY27 stood at Rs. 255 crore with margins falling to 10.7%, impacted by higher operating expenses including remediation costs at the Montreal facility and lower availability of high-margin SPECT radiopharmaceutical products.
In Radiopharmaceuticals, revenue increased 18% to Rs. 342 crore despite margin pressures; Radiopharmacy revenue grew 10% to Rs. 667 crore supported by expanded PET product volume and a US$60 million investment in new PET manufacturing sites.
Allergy Immunotherapy revenue rose 18% to Rs. 230 crore fueled by increased demand in US and international markets with a 30% EBITDA margin.
The company announced strategic agreements including a master services agreement for manufacturing a major oncology product and a distribution deal for a leading PET diagnostic product through new PET pharmacies.
Highlights
- 21% year-on-year revenue growth to Rs. 2,370 crore in Q2 FY27
- EBITDA at Rs. 255 crore with margin decline to 10.7%
- Rs. 800 crore raised through Non-convertible debentures for debt refinancing and capex
- 33% revenue increase in CDMO Sterile Injectables segment
- Continued growth in Radiopharmaceuticals and Radiopharmacy with capacity expansion plans
- Master services agreement signed for large oncology product manufacturing
Key Data Snapshot
What happened
- Jubilant Pharmova reported a 21% year-on-year revenue increase to Rs. 2,370 crore for the quarter ended September 30, 2026 (Q2 FY27).
- EBITDA for Q2 FY27 was Rs. 255 crore with margins declining to 10.7%, influenced by higher operating expenses and lower availability of certain radiopharmaceutical products.
- Reported PAT was Rs. 31 crore, with a margin of 1.3%.
- The company raised Rs. 800 crore through Non-convertible debentures to refinance existing debt and invest in capital expenditure.
Key details
- CDMO Sterile Injectables segment saw a 33% revenue growth to Rs. 522 crore, supported by technology transfers and new production lines including Line 3.
- Radiopharmaceuticals segment revenue increased 18% to Rs. 342 crore, despite margin pressure due to product availability.
- Radiopharmacy revenue grew 10% to Rs. 667 crore driven by volume increases in PET products and investment plans totaling over US$60 million for expanding PET manufacturing sites in the US.
- Allergy Immunotherapy business revenue grew 18% to Rs. 230 crore, with increased demand in US and international markets and a 30% EBITDA margin.
- A master services agreement was signed with a large innovator pharma company for manufacturing a major oncology product.
- An agreement was secured with a radiopharmaceutical player to distribute a leading PET diagnostic product through new PET pharmacies.
Strategic context
- The company announced plans to double the capacity of Ruby-Fill® at its Montreal facility with a CAD 94.5 million capital expenditure.
- Expansion of the US PET radiopharmacy network to nine sites is underway to become the second largest in the US.
- The restart of SPECT radiopharmaceutical production at Montreal is expected to improve supply in H2 FY27.
- Operating losses at the Montreal CMO facility are expected to reduce in FY28 through cost optimization.
Funding and capital details
- Jubilant Pharmova successfully raised Rs. 800 crore through Non-convertible debentures.
- The fund proceeds are intended for debt refinancing and capital expenditure plans to support business growth.
Highlights
- 21% year-on-year revenue growth to Rs. 2,370 crore in Q2 FY27
- EBITDA at Rs. 255 crore with margin decline to 10.7%
- Rs. 800 crore raised through Non-convertible debentures for debt refinancing and capex
- 33% revenue increase in CDMO Sterile Injectables segment
- Continued growth in Radiopharmaceuticals and Radiopharmacy with capacity expansion plans
- Master services agreement signed for large oncology product manufacturing
Disclosures
- Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Sobhagya Mercantile Ltd. Sets Extraordinary General Meeting for December 11, 2026, via Video Conferencing
Sobhagya Mercantile Limited has issued a public notice convening an Extraordinary General Meeting (EGM) scheduled for December 11, 2026, at 11:30 A.M. IST. The meeting will be conducted through video conferencing and other audio-visual means, with e-voting facilities provided to shareholders.
Read Full StoryAPL Apollo Tubes Denies Promoter Stake Sale Rumors Following Speculative News
APL Apollo Tubes Limited issued a clarification on November 20, 2026, denying any knowledge or communication regarding a proposed sale of promoter family shares amid speculative media reports.
Read Full StoryIndusInd Bank Conducts November 2026 Investor and Analyst Meetings in Chennai with Leading Asset Managers
On November 19, 2026, IndusInd Bank Limited conducted analyst and institutional investor meetings in Chennai, involving prominent asset management companies such as Franklin Templeton, Bandhan AMC, Axis AMC, and Motilal Oswal AMC. The bank clarified no unpublished price sensitive information was shared during these discussions.
Read Full Story